HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo.

Abstract
NO-donating aspirin (NO-ASA), a novel pharmacological agent currently undergoing clinical testing, consists of ASA to which a nitrate group is covalently linked via a spacer molecule. We synthesized the three positional isomers of NO-ASA with respect to the -CH(2)ONO(2) group (ortho, meta, and para) and examined whether this isomerism affects the biological activity of NO-ASA on HT-29 human colon cancer cells. The ortho- and para-isomers showed similar IC(50) values (1-5 microM) for cell growth inhibition over 72 h, whereas the IC(50) of the meta-isomer was 200 to 500 microM. The ortho- and para-isomers inhibited cell proliferation more potently than the meta-isomer. All three induced apoptosis but the ortho- and para-isomers also induced atypical cells (they maintain their shape but have diminished or absent nuclear material). Treatment for 3 weeks of Min (Apc(min)(/+)) mice, a model of intestinal cancer, with equimolar amounts of meta- and para-NO-ASA decreased the number of tumors in the small intestine by 36 and 59% (P < 0.01), respectively, compared with vehicle-treated controls, thus confirming their in vitro differences in potency. A structure-activity study of the three isomers revealed that substituting an aliphatic for the aromatic spacer or removing the -ONO(2) group profoundly diminished NO-ASA's ability to inhibit cell growth, whereas removal of the acetyl group on the ASA moiety did not affect cell growth inhibition. Thus, positional isomerism is critical for the pharmacological properties of NO-ASA against colon cancer and it should be taken into consideration in rational drug design.
AuthorsKhosrow Kashfi, Simona Borgo, Jennie L Williams, Jie Chen, Jianjun Gao, Athanasios Glekas, Francesca Benedini, Piero Del Soldato, Basil Rigas
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 312 Issue 3 Pg. 978-88 (Mar 2005) ISSN: 0022-3565 [Print] United States
PMID15528453 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Growth Inhibitors
  • N-acetyl-S-(alpha-methyl-4-(2-methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl ester
  • Nitrates
  • Nitric Oxide Donors
  • Proliferating Cell Nuclear Antigen
  • Nitric Oxide
  • Aspirin
Topics
  • Apoptosis (drug effects)
  • Aspirin (analogs & derivatives, pharmacology)
  • Cell Proliferation (drug effects)
  • Colonic Neoplasms (drug therapy, pathology)
  • Dose-Response Relationship, Drug
  • Growth Inhibitors (pharmacology)
  • HT29 Cells
  • Humans
  • Isomerism
  • Nitrates (pharmacology)
  • Nitric Oxide (metabolism)
  • Nitric Oxide Donors (pharmacology)
  • Proliferating Cell Nuclear Antigen (analysis)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: